Results of Creditors and General Meetings
Iconic Labs PLC
22 September 2022
Iconic Labs Plc - In Administration ("Iconic Labs" or the "Company")
Notice of Results of Creditors Meeting and General Meeting of Shareholders
Iconic Labs Plc (LSE:ICON hereby advises that it held a general meeting ("GM") earlier today.
The CVA Proposal was approved by the requisite majorities of the creditors at a meeting of the creditors held today at 11am.
At a meeting of the shareholders of the Company, held today at 2.00pm, all resolutions were duly passed on a poll vote.
Details of the proxy voting are shown in the table below.
| Votes For | % | Votes Against | % | Votes Total | Votes Withheld |
Ordinary resolutions: | ||||||
(1) Approval of the Company Voluntary Arrangement ("CVA"). | 10,009,834,608
| 97.49 | 257,331,813
|
2.51
| 10,267,166,421 |
48,068,796
|
(2) To empower the directors to generally allot relevant equity securities in respect of the CVA | 10,240,735,765
|
99.74
| 26,430,656
|
0.26
| 10,267,166,421
|
48,068,796
|
(3) To empower the directors to generally allot relevant equity securities to promote the success of the Company | 10,240,225,765
|
99.74
| 26,430,656
|
0.26
| 10,266,656,421
|
48,578,796
|
Special resolutions: | ||||||
(4) Subject to the passing of Resolution 2, to disapply the pre-emptive rights in respect of the relevant equity securities to be allotted in respect of CVA Proposal. | 10,009,324,608
|
97.49
| 257,331,813
|
2.51
| 10,266,656,421
|
48,578,796
|
(5) Subject to the passing of Resolution 3, to disapply the pre-emptive rights in respect of the relevant equity securities to be allotted to promote the success of the Company. | 10,240,225,765
|
99.74
| 26,430,656
|
0.26
| 10,266,656,421
|
48,578,796
|
The full text of each of the resolutions is set out in the Notice of AGM, available on the Company's website (www.iconiclabs.co.uk).
Market Abuse Regulation (MAR) Disclosure - Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the release of this announcement.
For further information, please visit the Company's website www.iconiclabs.co.uk or contact the Company via [email protected].
END
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.